According to filings with the U.S. Securities and Exchange Commission, Vogenx is raising up to $5,000,000.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About Vogenx
Vogenx is a clinical-stage life science and drug development company dedicated to improving the lives of patients suffering from dysfunctions in human metabolism. The company focuses on developing novel therapeutics for significant metabolic and gastrointestinal diseases, including post bariatric hypoglycemia (PBH), gastroparesis, and obesity. Their lead compound is a first-in-class, oral, small molecule drug candidate designed to inhibit postprandial glucose absorption and reduce the secretion of insulin and gastric inhibitory peptide (GIP). Vogenx aims to address unmet medical needs through its pipeline of innovative treatments.

To learn more about Vogenx, visit https://vogenx.com/
Vogenx Linkedin Page: https://www.linkedin.com/company/vogenx-inc/

Contact:
Steven Delmar, Chief Financial Officer
919-659-5677

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.